Mostafa Faisal Mohammed Saleh: Exploring the Impact of PNH Clones in Aplastic Anemia Across Different Treatment Strategies
Mostafa Faisal Mohammed Saleh, Associate Professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn about a recent article by Alfadil Haroon, published in Blood Research։
”Just out in Blood Research journal, Dr. Alfadil Haroon from King Faisal Specialist Hospital and Research Centre Riyadh presents a comprehensive analysis of PNH clones in aplastic anemia, exploring their impact across IST and HSCT.
Number of patients equals 207 including PNH positive patients equals 64 which corresponds to 30.9 percent․
Immunosuppressive therapy in 104 patients and hematopoietic stem cell transplantation in 103 patients․
Overall survival with immunosuppressive therapy was 100 percent in PNH positive patients compared with 72 percent in PNH negative patients․
Overall survival after hematopoietic stem cell transplantation was 100 percent in PNH positive patients compared with 90 percent in PNH negative patients and this difference was not statistically significant․
Chronic graft versus host disease occurred in 4 percent of PNH positive patients compared with 27 percent in PNH negative patients․
Acute graft versus host disease relapse and graft failure showed similar rates between groups․
PNH clone size showed no impact on outcomes․
Takeaway is that PNH positive status is associated with better survival and lower rates of chronic graft versus host disease.”
Title: Prognostic significance of PNH clones in aplastic anemia treated with immunosuppression or allogeneic HSCT: a 20-year single-center experience
Authors: Alfadil Haroon, Hazzaa Alzahrani, Mostafa F. Mohammed Saleh, Ali Aalahmari, Shaykhah Alotaibi, Tusneem Elhassan, Feras Alfraih, Fahad Alsharif, Syed O. Ahmed, Fahad Almohareb, Riad El Fakih, Mahmoud Aljurf
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 10:32Natalie Arnold: The Lp(a) Puzzle – Why Lower Levels May Not Tell the Whole Story
-
Nov 9, 2026, 10:22ISBT Opens Applications for the I TRY IT Programme 2027
-
Nov 9, 2026, 10:08Ibrahim Mansoor: Rare Tests, Common Diseases – Rethinking Autoimmune Diagnostics
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services